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IN JANUARY of 1984, the results of the decade-long Lipid Research Clinics (LRC) Coronary Primary Prevention Trial were reported.' The results received widespread attention through the news media and have been much discussed and sometimes hotly debated. It is the intention of this article to briefly review this study and some of the findings that led to its initiation in order to detail where we are now and to suggest future directions in research and patient care.
For several decades evidence has been accumulating to indicate that there is a causal relationship between high cholesterol levels in blood and coronary atherosclerosis. The evidence for the cholesterol/atherogenesis connection includes results of direct morphologic studies of the atherosclerotic plaque itself (which by definition contains cholesterol), as well as results of studies in animals (including nonhuman primates in which plaque regression has been demonstrated with cholesterol lowering), and data from metabolic, genetic, and prospective and retrospective epidemiologic studies in man. [3] [4] [5] Despite all of this evidence, some have questioned tne cholesterol/atherogenesis connection because it has not been demonstrated directly in man that lowering plasma cholesterol (low-density lipoprotein or LDL) levels reduces progression of atherosclerotic plaque or incidence of heart attack and death from cardiac causes. These individuals point out that epidemiologic findings may represent circumstantial associations and that studies in animals may not necessarily be relevant and demand direct clinical trial evidence in man.
Review of results of all the clinical trials performed before the LRC Coronary Primary Prevention Trial and the NHLBI Type II Intervention Study in aggregate reveals suggestive but not definitive evidence of the value of lowering cholesterol levels. What appeared to be lacking from the design of most of the trials was an appreciation of the logistic (the study power and sample size) requirements essential for a trial designed to test the effects of lowering cholesterol levels on the progression of coronary artery disease.
Many of the clinical trials performed in the past lacked important features. The failure to completely randomize often meant that there was not a comparable control group to compare with the treatment group. The lack of a double-blind design made it difficult to interpret even the most objective of end points. Many of the trials suffered from lack of adequate numbers of participants or adequate follow-up time. In still others adherence of study subjects to diet or other regimens was not documented, resulting in an inadequate cholesterol differential. Finally, when drugs that lower lipid levels are given to subjects, an awareness of the potential side effects of the drugs is necessary. All these factors were reviewed by the National Heart, Lung, and Blood Institute's Atherosclerosis Task Force,6 which in 1972 recommended (in good part because of logistics) against a national diet-heart trial and for several of the more defined studies that have recently been concluded.
The LRC Coronary Primary Prevention Trial. The LRC Coronary Primary Prevention Trial was a randomized, multicenter, placebo-controlled double-blind study. ' 2 It enrolled a large number of patients (3806) and was designed to follow them all for a minimum of 7 years to a primary end point of heart attack or cardiac death. It was carried out scrupulously in 12 lipid research clinics, 11 in the United States and one in Canada. The participants were all men (to increase the likelihood of events) between the ages of 35 and 59 years with cholesterol levels above 265 mg% (the 95th percentile for the United States). Volunteers were eligible only if they had no evidence of coronary artery disease on examination or by history and had elevated cholesterol levels. Excluded from the trial were subjects taking lipid-lowering drugs or with hypertension or another disease likely to limit their life expectancy.
Subjects were seen monthly, at first in part to eliminate the faint of heart, and were placed on a modest modified fat diet designed not so much to lower cholesterol as to offer something to all volunteers entering the trial. (In fact, the power of the study would have been greater and the sample size requirement less if one group received no treatment to lower cholesterol levels and in the other group cholesterol level was lowered by a fixed percentage.) The diet was a modified low-fat, low-cholesterol diet (much less stringent than the current American Heart Association dietary recommendation)7 containing about 400 mg of cholesterol and a P/S ratio of about 0.8. It was designed to achieve approximately a 3% to 4% reduction in cholesterol.
After five clinic visits the volunteers were randomly assigned to one of two equal groups. The randomization procedure created two comparable groups, identical at the start of the study with respect to clinical characteristics and with a mean age of 47 years and a mean cholesterol level of 291 mg%. The groups were still identical 7 years later except that one had a considerably lower cholesterol level. The lipid-lowering drug cholestyramine was selected for study because it is a known effective LDL-lowering agent that is not absorbed, i.e., it is nonsystemic and does not have the potential systemic effects seen with agents like clofibrate.' It was also chosen because a placebo form was known to be available.
The remarkable feature of the LRC Coronary Primary Prevention Trial, in addition to its magnitude (3086 men enrolled, 193,000 clinic visits, 1,055,000 clinic data forms, 341,000 blood tests and 72,000 electrocardiograms) and cost (over $150 million), was the fact that complete follow-up was achieved at the end of the study so that the vital status of all 3806 patients randomized into the trial was known.
With use of intention-to-treat analysis and thereby including both those patients who took cholestyramine regularly and those who took none during most of the trial, it was found that the average 8% differential in cholesterol and 11% differential in LDL between the placebo and treatment group over the 7 years of the study was associated with a statistically significant 19% reduction in occurrence of the primary end point of definite heart attack or cardiac death. This consisted of a 24% reduction in definite cardiac death and a 19% reduction in definite heart attack.
In the group of men randomly assigned to receive cholestyramine the wide range in degree of compliance to the prescribed drug regimen produced a wide differential in cholesterol reductions and thereby created a study within a study. Analysis of these data demonstrated that as compliance increased, reduction in cho-Vol. 72, No. 4, October 1985 lesterol level increased, as did the reduction in incidence of definite heart attack and cardiac death. With multivariate analyses it was demonstrated that reduction in cholesterol level and not packet ingestion per se explained the observed reduction in risk. In fact, statistical analysis allowed the development of a linear regression model in which a 25% lowering of cholesterol level, achievable with a full dose of medicine, was associated with a 50% reduction in risk. It is this finding that is responsible for the popularized observation that for every 1% reduction in cholesterol, there was a 2% reduction in incidence of heart attack and cardiac death.
What was perhaps most impressive about the findings of the LRC Coronary Primary Prevention Trial was their consistency. All the cardiovascular events that were recorded, from the definitive end point of heart attack or death from cardiac causes to other "softer" end points, indicated a benefit of treatment (table 1) . For example, subjects underwent stress exercise testing every 6 months during the study. Results were positive in 260 of the patients on cholestyramine and in 345 of the patients on placebo, which indicates a reduction in risk of some 25% (p = < .001) for the patients receiving the drug. In the placebo group 287 patients developed angina, compared with 235 patients in the cholestyramine group, a reduction of 20%. In the cholestyramine group, 93 patients required coronary bypass surgery vs 112 in the placebo group. Although much smaller in number, there were similar reductions in the development of congestive heart failure, intermittent claudication, and resuscitated coronary arrest in the drug-treated group.
In 1976, in the Annals of Internal Medicine,9 those who supported the lipid hypothesis were challenged in an article entitled "Whether Rather Than How." It was suggested that it was not enough to demonstrate a curvilinear relationship between cholesterol and heart disease in prospective studies like the Framingham Study but rather that it was necessary to demonstrate that if cholesterol level was lowered the risk of heart disease was indeed reduced. This is what the LRC Coronary Primary Prevention Trial has done.
In addition to the results of the LRC Coronary Primary Prevention Trial, recent secondary prevention trials have further supported the value of lowering cholesterol level. In the NHLBIs Type II Coronary Intervention Trial,9 '°a design similar to that of the LRC Coronary Primary Prevention Trial was used in hypercholesterolemic patients with existing coronary disease. Change in coronary artery lesions at 0 and 5 years, as demonstrated by comparative angiography, was the end point. It was demonstrated that lowering cholesterol levels was associated with a decrease in progression of atherosclerotic plaque and that this change in progression was related to both a fall in LDL and an increase in high-density lipoprotein (HDL).
Considering all available evidence, we have in fact fulfilled what might be thought of as Koch's postulates for cholesterol and atherosclerosis. Not only have we determined that there is cholesterol in all atherosclerotic plaques and that when the blood levels of cholesterol increase, plaques and the clinical sequelae of plaque progression increase, but we can also demonstrate that when cholesterol levels are lowered the development of plaque and its sequelae, heart attack and cardiac death, decrease.
Extrapolating the evidence. The results of LRC Coronary Primary Prevention Trial are quite clear. What is not so clear is how far these basic findings can be generalized. Some would choose not to extrapolate at all and suggest that the findings are applicable to middle-aged men with cholesterol levels over 265 mg% who take bile acids sequestrants only. That would be a still sizeable number of individuals, some 1 to 2 million in the American population. There is little reason, however, to limit the extrapolation so narrowly. The age group from 35 to 59 years old in this study was chosen arbitrarily. There is no reason to think that lowering of cholesterol levels would not be beneficial in individuals below age 35 or above age 59. Similarly, women were excluded from this study because as a group they do not suffer many cardiac events between ages 35 and 59. However, since in women cholesterol is a major risk factor and coronary artery disease is still the major cause of death, there is every reason to believe that the study results can and should be extrapolated to women. Furthermore, since there is no magic cutoff point above which cholesterol is dangerous, but rather a graded risk relationship at least down to a cholesterol level of 180 mg%, there is every reason to think that the members of the population in the top four quintiles with respect to cholesterol level would benefit from its reduction. Selected reference values for total and lipoprotein cholesterol obtained in the LRC North American Prevalence Study are presented in table 2. If results are extrapolated to women, a wider age range, and to those in the top quintile of cholesterol level, about 40 to 50 million Americans could be considered at risk, a population as large as those now considered at risk of hypertension. With regard to hypertension, since the start of the National High Blood Pressure Education Program in 1972" the public health impact of focusing health care professional and public attention has been impressive.
Although more controversial, there are others, like the members of the panel for the recent NIH Consensus Development Conference on lowering of cholesterol, 12 who after reviewing all available evidence extrapolate the potential benefits of lowering cholesterol even further and recommend low-cholesterol diets for the entire American population (except for children under the age of 2). Dietary reduction of plasma cholesterol is safe and cheap and the mechanism by which cholestyramine lowers cholesterol (recently shown to be by increasing hepatic LDL-receptor activity) appears to be similar to the mechanism by which low-fat, lowcholesterol diets do the same. The 10% to 15% lowering of cholesterol level that is possible in the average American with the American Heart Association's prudent phase I diet7 could have an enormous impact on cardiovascular morbidity and mortality in the United States.
Questions to be answered. Today it is no longer a question of whether to treat those with high cholesterol levels, but rather when, whom, and how to treat? As with any clinical trial, the LRC Coronary Primary Prevention Trial has resulted in many new questions requiring further research. For one, is reduction of LDL by any means beneficial? The LRC Coronary Primary Prevention Trial has demonstrated the benefit of low- ering cholesterol levels with the drug cholestyramine. Since the mechanism is similar, others have suggested that diet should work equally well. What about other lipid-lowering drugs? Should we not be suspicious and cautious in extrapolating the results with cholestyramine to other lipid-lowering agents since findings of both the European Primary Prevention Trial and the Coronary Drug Project indicate that some of these drugs may have serious adverse side effects?8 Furthermore, in the LRC Coronary Primary Prevention Trial and in the NHLBI Type IL Intervention Trial a benefit from reduction of LDL and from an increase in HDL was observed. 12a An independent benefit seemed to be apparent with small increments in HDL. Should we therefore now be focusing on HDL as well? Is elevation of HDL levels by any means beneficial? Should we be attempting to raise HDL by nonpharmacologic methods like exercise and weight reduction? And what about pharmacologic approaches to raising the HDL level? There are several drugs available for this purpose. Would they be of benefit in preventing heart disease?
In the LRC Coronary Primary Prevention Trial, the major criteria for entry as well as for monitoring and follow-up was total and LDL cholesterol. In the future, should our design to treat and follow-up patients be based on the total cholesterol level or should we be focusing on lipoprotein cholesterol levels? There is Vol. 72, No. 4, October 1985 much evidence to suggest that treating specific lipoprotein excesses with specific diets and drugs is more effective and that by defining the lipoprotein excess we can provide a more specific and effective regimen for lipid lowering. In the future, will the measurement of lipoprotein apoprotein levels give us a more useful index by which to guide treatment and follow-up than total or lipoprotein cholesterol levels? Immunoassay techniques for the lipoprotein apoproteins are now being developed and tested. It has been suggested that measurement of apoprotein levels may provide more specific and sensitive coronary artery risk information. Evidence is accumulating that measurement of both apoprotein B and apoprotein A, gives useful and predictive information with regard to coronary heart disease risk.
In the public health arena the potential benefit of lowering cholesterol levels is so great that we must explore the optimal methods of enhancing changes in these levels. Among the health care issues raised are questions such as: How can we reduce the cost of lipidlowering drugs? The only drugs now shown to be beneficial, the bile acid sequestrants, are expensive, costing patients well over a $100.00 a month. Will the fact that lower cholesterol levels have now been shown to be beneficial lead to increased activity in industry and to the development of more palatable and less costly lipid-lowering drugs? And how can we ensure patient adherence to diet and drug therapy? Even the modest diet changes that are required to reduce the amount of saturated fat and cholesterol in a cholesterol-lowering diet require some degree of motivation and adherence by patients. Habits of a lifetime are difficult to change. We must both educate and motivate our patients. How can we maximize this? And, what are the implications for the meat, dairy, and other food industries? Already a number of food manufacturers are preparing foods lower in saturated fat and cholesterol. The potential in this area is enormous, as is the need to educate Americans on the reading of food labels and the nature of dietary fat and cholesterol.
Finally, a major health care issue that has been the subject of some debate deals with the value of intervention in high-risk subjects vs a mass population approach. Some argue that we should be screening the population at large and treating those with the highest levels of cholesterol. Others argue that it would be much more cost effective to seek to lower the cholesterol level in everyone through diet, thereby reducing the cholesterol-attributable risk in the entire population. As with this issue in hypertension (as well as other risk factor interventions), the answer does not appear to be either/orthe answer is both. There is a clear benefit to identifying and treating individuals at high risk in the population and there is a clear benefit with respect to cost efficiency in seeking to lower the average American cholesterol level through a mass population approach.
When, whom, and how to treat. In terms of when to treat, it would appear that since atherosclerosis begins in the first two decades of life, and is episodically progressive over time, there would be little reason to delay cholesterol reduction. This is especially true if the method is diet, the use of which can be considered safe after age 2 and still appropriate and effective beyond age 65.
The NIH Consensus statement12 on lowering blood cholesterol recommends that all adults with "high risk blood cholesterol levels" (values above the 90th per- centile) be treated intensively by diet and, if the response is inadequate, with appropriate drugs. The statement further recommends that those with "moderate risk blood cholesterol levels" (values between the 75th and 90th percentiles) be treated intensively by dietary means and states that only a-small proportion should require drug treatment. Their recommended cholesterol values for defining men and women at "moderate and high risk" requiring treatment are presented in table 3. Some experts recommend a more conservative approach while still others would be even more aggressive.
I have used an approach relatively consistent with the NIH recommendations: All individuals (men and women) with cholesterol levels of over 200 mg% should be considered candidates for dietary treatment; treatment is especially indicated for individuals with other risk factors, such as previous coronary artery bypass surgery or diabetes, end-stage renal disease, or other disorders known to be associated with accelerated atherosclerosis.
Every patient should know what his or her plasma cholesterol level is. Any level of cholesterol of 200 mg% or higher (or 175 mg% or higher in children) should be revealed to the patient (or parent) and, if it is due to LDL excess, a diet should be suggested. A cholesterol-lowering diet should certainly be prescribed for any adult patient whose cholesterol level, due to LDL excess, is over 230 mg%. Those patients with other risk factors for coronary heart disease, or with cholesterol levels above 260 mg%, in whom cholesterol level does not fall below 230 mg% with dietary therapy (and the elevation is due to an increase in LDL) should be considered for drug therapy.
In terms of how to treat, it is important to establish a baseline and obtain several measurements so that it can be determined that the patient in truth has an elevated cholesterol level. Secondary causes should be ruled out. The first intervention tried should always be diet. In some patients an improper diet or sensitivity to dietary fat may be the cause of the hypercholesterolemia. In others, diet will help lower the cholesterol enough so that less drug therapy will be necessary, thus lowering costs and the incidence of drug-induced side effects. When deciding upon a treatment strategy, it is important, when possible, to change one factor at a time. If it is known that the patient has complied with therapy, an ineffective regimen should not be continued beyond 8 weeks. When a drug is used, it should be one appropriate for the type of lipoprotein excess the patient has and blood samples should be obtained from the patient regularly. The latter will avoid the possibil-ity of missing inapparent side effects and serve to motivate the patient.
In conclusion, we have now entered into a new era. The question is no longer whether or not lowering cholesterol is beneficial. The questions now, and that have been discussed herein, include when, whom, and how to treat. These are questions that will be debated for a period of time, but practicing physicians today, especially those treating middle-aged Americans at risk for coronary disease, can for the first time do more than say that a high cholesterol level is a risk factor. If a patient is found to have an elevated cholesterol level, a cholesterol-lowering regimen can be prescribed with the knowledge that the patient will likely live longer and better as a result.
